GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026, related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026. This request has stayed any suspension or delisting action, allowing GeoVax's common stock to continue trading on The Nasdaq Capital Market under the symbol "GOVX" at least through the hearing and any extension period granted by the Panel. At the hearing, GeoVax intends to present its plan to regain and maintain compliance with Nasdaq listing standards.
David Dodd, Chairman and CEO of GeoVax, commented, "We remain committed to maintaining GeoVax's Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution. We continue to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen our manufacturing and global preparedness capabilities, and engage potential strategic, funding and development partners across our portfolio." He added that the company's focus remains on building long-term value from its vaccine and immuno-oncology programs while addressing near-term corporate and financing priorities.
The Nasdaq listing appeal is significant because a delisting could harm investor confidence and limit access to capital, which is critical for a clinical-stage biotech. By staying listed, GeoVax can continue to fund its priority program, GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. This comes amid growing global emphasis on vaccine supply resilience and biodefense, making GeoVax's work increasingly relevant.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
GeoVax's ability to maintain its Nasdaq listing is crucial for executing these strategic priorities, as it provides ongoing access to public markets and reinforces credibility with partners and investors. The outcome of the appeal will be closely watched, as it could impact the company's ability to raise necessary capital to continue and complete development. For more information, visit www.geovax.com.
